Diversified healthcare firm Ainos Inc (OTCMKTS:AIMD) has been in the middle of a strong downward spiral in the markets over the course of the past week.
Trading Data
On Tuesday, AIMD stock ended flat at $0.45 with more 1.1k shares, compared to its average volume of 1K shares. The stock has moved within a range of $0.4500 – 0.4500 after opening trade at $0.68.
Announces Strategic Relationship with InnoPharmax
During the period, the stock has tanked by as much as 35% and in this situation, it may be a good time for investors to perhaps work out if the sharp fall may be an opportunity to pick up the Ainos stock at a discount. Yesterday, the company was in focus after it announced that it had inked a Development and Sales Agreement with the specialty pharmaceutical firm InnoPharmax Inc.
It was a major development for the company and it remains to be seen if it can help in reversing the sentiments about the Ainos stock among investors in the coming days. As per the terms of the agreement between the two parties, they are going to collaborate on the on the development of a CICCT or a cytotoxin-induced complementary combined therapy that is going to be administered orally.
The product in question is meant for the treatment of patients suffering from COVID-19 infection. More importantly, the product could also help in tackling other viral infections. It may be a good time to add the stock to your watch lists.
Key Quote
“We believe that CICCT combined with interferon may increase the production of human cytotoxin, an autoimmune hormone that is reported to inhibit viruses,” said Ainos’ CEO Chun-Hsien Tsai. “The high level of COVID-19 cases — still nearly 100,000 new confirmed cases despite increasing vaccination rates reported each day and more than 1,000 confirmed deaths during the past week in the U.S. alone according to the U.S. Department of Health and Human Services – suggests that the world needs a broader range of effective antiviral therapies,” he observed.
